First-order effects

• Medical researchers running the initial ResearchKit studies gain a recruitment funnel that reaches any eligible iPhone owner instead of patients who walk through a hospital door, while volunteers get a one-tap path into trials.
• Developers acquire a reusable survey-and-consent UI toolkit, and some — like Mike Rundle, who asked publicly how it fits non-health apps — immediately see it as general-purpose interface scaffolding rather than medical-only infrastructure.

Second-order effects

• Academic institutions and pharma-sponsored studies face pressure to offer an iOS enrollment channel of their own or cede sample volume to the apps Apple showcases first, making App Store visibility a de facto gatekeeper for study reach.
• Privacy scrutiny intensifies around health data flows — the 'used or abused' concern — forcing Apple and participating researchers to defend consent and data-handling practices as a condition of keeping volunteer trust.

Third-order effects

• If the pattern holds, longitudinal medical research reorganizes around consumer platforms rather than clinical sites, with sustained retention — the weak spot later coverage identified — determining whether platform-mediated cohorts can replace traditional trial populations.
• The same citizen-participation model invites regulatory attention to how consumer devices mediate informed consent, since a phone-based funnel concentrates both recruitment power and data stewardship with one vendor.